Cargando…

Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol

SIMPLE SUMMARY: Relationships between drug concentrations in blood and efficacy and/or toxicity have been reported for up to 80% of oral anticancer drugs (OADs). Most OADs exhibit highly variable drug concentrations at the approved dose. This may result in a significant proportion of patients with s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mc Laughlin, Anna M., Schmulenson, Eduard, Teplytska, Olga, Zimmermann, Sebastian, Opitz, Patrick, Groenland, Stefanie L., Huitema, Alwin D. R., Steeghs, Neeltje, Müller, Lothar, Fuxius, Stefan, Illerhaus, Gerald, Joerger, Markus, Mayer, Frank, Fuhr, Uwe, Holdenrieder, Stefan, Hempel, Georg, Scherf-Clavel, Oliver, Jaehde, Ulrich, Kloft, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699239/ https://www.ncbi.nlm.nih.gov/pubmed/34944899 http://dx.doi.org/10.3390/cancers13246281

Ejemplares similares

Therapeutic drug monitoring of oral targeted antineoplastic drugs
por: Mueller-Schoell, Anna, et al.
Publicado: (2020)

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
por: Groenland, Stefanie L., et al.
Publicado: (2018)

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review
por: van Dyk, Madelé, et al.
Publicado: (2022)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: Verheijen, Remy B., et al.
Publicado: (2017)

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: van der Kleij, Maud B. A., et al.
Publicado: (2023)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
por: Groenland, Stefanie L., et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
por: Crombag, Marie-Rose B.S., et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
por: Gerner, Bettina, et al.
Publicado: (2021)

Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil
por: Schmulenson, Eduard, et al.
Publicado: (2022)

Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approach
por: Schmulenson, Eduard, et al.
Publicado: (2020)

A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients
por: Ojara, Francis Williams, et al.
Publicado: (2023)

C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework
por: Nassar, Yomna M., et al.
Publicado: (2023)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer
por: Kloft, C, et al.
Publicado: (2003)

Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics
por: Molenaar‐Kuijsten, Laura, et al.
Publicado: (2021)

The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging
por: Haider, Malik Salman, et al.
Publicado: (2021)

Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges
por: van Leuven, Jason, et al.
Publicado: (2023)

PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study
por: Heinhuis, Kimberley M, et al.
Publicado: (2020)

New opportunities for kinase drug repurposing and target discovery
por: Knapp, Stefan
Publicado: (2018)

Impact of Bariatric Surgery in the Short and Long Term: A Need for Time-Dependent Dosing of Drugs
por: Lau, Cedric, et al.
Publicado: (2023)

Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle
por: El Amrani, Mohsin, et al.
Publicado: (2019)

Predicting the Reliability of Drug-target Interaction Predictions with Maximum Coverage of Target Space
por: Peón, Antonio, et al.
Publicado: (2017)

Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line
por: Saafan, Hisham, et al.
Publicado: (2021)

SuperPred: drug classification and target prediction
por: Dunkel, Mathias, et al.
Publicado: (2008)

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
por: Schlender, Jan-Frederik, et al.
Publicado: (2016)

Introduction to Drugs and Drug Targets
por: Zanders, Edward D.
Publicado: (2011)

Drug-drug relationship based on target information: application to drug target identification
por: Park, Keunwan, et al.
Publicado: (2011)

A screen to identify drug resistant variants to target-directed anti-cancer agents
por: Azam, Mohammad, et al.
Publicado: (2003)

Mining Natural Products for Macrocycles to Drug Difficult Targets
por: Begnini, Fabio, et al.
Publicado: (2020)

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

Healthy volunteers in first‐in‐human oncology drug development for small molecules
por: de las Heras, Begoña, et al.
Publicado: (2021)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice
por: Simeoli, Raffaele, et al.
Publicado: (2022)

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
por: Veerman, G.D. Marijn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_32a596051lfpjrkd9i4j90vp0k